These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35485345)

  • 81. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.
    Lepage MA; Rozza N; Kremer R; Grunbaum A
    Clin Toxicol (Phila); 2021 Jul; 59(7):644-647. PubMed ID: 33641562
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
    Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H
    PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
    Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F
    Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections.
    Purwati ; Budiono ; Rachman BE; Yulistiani ; Miatmoko A; Nasronudin ; Lardo S; Purnama YI; Laely M; Rochmad I; Ismail T; Wulandari S; Setyawan D; Rosyid AN; Setiawan HW; Wulaningrum PA; Asmarawati TP; Marfiani E; Yuniati SK; Fuadi MR; Endraswari PD; Purwaningsih ; Hendrianto E; Karsari D; Dinaryanti A; Ertanti N; Ihsan IS; Purnama DS; Indrayani Y
    Biochem Res Int; 2021; 2021():6685921. PubMed ID: 33628506
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
    Santos JR; Muñoz-Moreno JA; Moltó J; Prats A; Curran A; Domingo P; Llibre JM; McClernon DR; Bravo I; Canet J; Watson V; Back D; Clotet B
    PLoS One; 2013; 8(7):e70201. PubMed ID: 23922957
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
    Wang B; Li D; Liu T; Wang H; Luo F; Liu Y
    BMC Infect Dis; 2020 Oct; 20(1):723. PubMed ID: 33008327
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
    Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.
    Huang X; Xu Y; Yang Q; Chen J; Zhang T; Li Z; Guo C; Chen H; Wu H; Li N
    Sci Rep; 2015 Feb; 5():8528. PubMed ID: 25704206
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
    Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
    Moneer O; Daly G; Skydel JJ; Nyhan K; Lurie P; Ross JS; Wallach JD
    BMJ; 2022 May; 377():e069400. PubMed ID: 35537738
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
    Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH
    Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
    Bunupuradah T; Chetchotisakd P; Jirajariyavej S; Valcour V; Bowonwattanuwong C; Munsakul W; Klinbuayaem V; Prasithsirikul W; Sophonphan J; Mahanontharit A; Hirschel B; Bhakeecheep S; Ruxrungtham K; Ananworanich J;
    J Neurovirol; 2012 Dec; 18(6):479-87. PubMed ID: 22993101
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
    Hassaniazad M; Farshidi H; Gharibzadeh A; Bazram A; Khalili E; Noormandi A; Fathalipour M
    J Med Virol; 2022 Jul; 94(7):3184-3191. PubMed ID: 35292989
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine.
    Tanaka T; Okamoto M; Matsuo N; Naitou-Nishida Y; Nouno T; Kojima T; Nishii Y; Uchiyashiki Y; Takeoka H; Nagasaki Y
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984543
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone.
    Suryantoro SD; Thaha M; Pranawa ; Santoso D; Mardiana N; Widodo ; Aditiawardana ; Tjempakasari A; Ardhany AR; Pramudya D; Hertanto DM; Febriane E; Meryana ; Angela M; Muliono AC; Tanuwidjaja H; Setiawan P; Sugiarto D
    J Infect Dev Ctries; 2021 Sep; 15(9):1257-1262. PubMed ID: 34669593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.